thalidomide has been researched along with Liver Cirrhosis, Biliary in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Liver Cirrhosis, Biliary: FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has been reported to be effective in treating graft-versus-host disease, a condition with many clinical and pathological similarities to primary biliary cirrhosis." | 9.07 | Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. ( Burroughs, AK; Epstein, O; McCormick, PA; McIntyre, N; Scheuer, PJ; Scott, F, 1994) |
| "Thalidomide has been reported to be effective in treating graft-versus-host disease, a condition with many clinical and pathological similarities to primary biliary cirrhosis." | 5.07 | Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. ( Burroughs, AK; Epstein, O; McCormick, PA; McIntyre, N; Scheuer, PJ; Scott, F, 1994) |
| "Thalidomide decreased the PVP and IHR through the attenuation of anandamide-induced constrictive response, decreasing the production of TNF-alpha, IL-6 and TXA(2) in the liver and the suppression of hepatic fibrogenesis of rats with biliary cirrhosis of this study." | 3.75 | Inhibition of hepatic tumour necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers. ( Chau, GY; Huang, YT; Lee, FY; Lee, KC; Lee, SD; Lin, HC; Loong, CC; Yang, YY, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández-Martínez, E | 1 |
| Pérez-Hernández, N | 1 |
| Muriel, P | 1 |
| Pérez-Alvarez, V | 1 |
| Shibayama, M | 1 |
| Tsutsumi, V | 1 |
| Yang, YY | 2 |
| Huang, YT | 2 |
| Lin, HC | 2 |
| Lee, FY | 2 |
| Lee, KC | 2 |
| Chau, GY | 2 |
| Loong, CC | 2 |
| Lai, CR | 1 |
| Lee, SD | 2 |
| McCormick, PA | 1 |
| Scott, F | 1 |
| Epstein, O | 1 |
| Burroughs, AK | 1 |
| Scheuer, PJ | 1 |
| McIntyre, N | 1 |
| Rhoton, AJ | 1 |
1 trial available for thalidomide and Liver Cirrhosis, Biliary
| Article | Year |
|---|---|
Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study.
Topics: Biopsy; Double-Blind Method; Female; Humans; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; | 1994 |
4 other studies available for thalidomide and Liver Cirrhosis, Biliary
| Article | Year |
|---|---|
The thalidomide analog 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanoic acid improves the biliary cirrhosis in the rat.
Topics: Animals; Fibrosis; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Necrosis; Rats; Rats, Wista | 2009 |
Thalidomide decreases intrahepatic resistance in cirrhotic rats.
Topics: Animals; Cell Movement; Immunosuppressive Agents; Leukocyte Common Antigens; Leukocytes; Lipopolysac | 2009 |
Inhibition of hepatic tumour necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers.
Topics: Animals; Arachidonic Acids; DNA Primers; Endocannabinoids; Enzyme-Linked Immunosorbent Assay; Gene E | 2009 |
Role for thalidomide in primary biliary cirrhosis treatment?
Topics: Humans; Liver Cirrhosis, Biliary; Thalidomide | 1993 |